Clinical diagnostic value of American College of Radiology thyroid imaging report and data system in different kinds of thyroid nodules

Ziwei Zhang and Ning Lin*

Abstract

Background: To evaluate the diagnostic value of American College of Radiology (ACR) score and ACR Thyroid Imaging Report and Data System (TI-RADS) for benign nodules, medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) through comparing with Kwak TI-RADS.

Methods: Five hundred nine patients diagnosed with PTC, MTC or benign thyroid nodules were included and classified into the benign thyroid nodules group (n = 264), the PTC group (n = 189) and the MTC group (n = 56). The area under the curve (AUC) values were analyzed and the receiver operator characteristic (ROC) curves were drawn to compare the diagnostic efficiencies of ACR score, ACR TI-RADS and Kwak TI-RADS on benign thyroid nodules, MTC and PTC.

Results: The AUC values of ACR score, ACR TI-RADS and Kwak TI-RADS for distinguishing malignant nodules from benign nodules were 0.914 (95%CI: 0.886–0.937), 0.871 (95%CI: 0.839–0.899) and 0.885 (95%CI: 0.854–0.911), respectively. In distinguishing of patients with MTC from PTC, the AUC values of ACR score, ACR TI-RADS and Kwak TI-RADS were 0.650 (95%CI: 0.565–0.734), 0.596 (95%CI: 0.527–0.664), and 0.613 (95%CI: 0.545–0.681), respectively. The AUC values of ACR score, ACR TI-RADS and Kwak TI-RADS for the discrimination of patients with MTC, PTC or benign nodules from patients without MTC, PTC or benign nodules were 0.899 (95%CI: 0.882–0.915), 0.865 (95%CI: 0.846–0.885), and 0.873 (95%CI: 0.854–0.893), respectively.

Conclusion: The ACR score performed the best, followed ex aequo by the ACR and Kwak TI-RADS in discriminating patients with malignant nodules from benign nodules and patients with MTC from PTC.

Keywords: Diagnostic value, MTC, PTC, ACR score, ACR TI-RADS

Background

Thyroid nodule is a kind of disease with scattered lesions caused by local abnormal growth of thyroid cells with a high incidence in the general population [1]. The detection rate of thyroid nodule is 3%-7% by palpation, and can be as high as 20%-76% by high-resolution ultrasound [2]. Approximately 1.6%-12% thyroid nodules are reported to be malignant, which refers to thyroid cancer [3]. Due to the increasing application of imaging diagnostic technology, the incidence of thyroid cancer continues to rise worldwide [4]. Papillary thyroid carcinoma (PTC), arising from the thyroid follicular cells, is the most common primary thyroid malignancy, accounting for more than 80% of thyroid cancers, and PTC patients generally have a good prognosis [5]. Medullary thyroid carcinoma (MTC), arising from the parafollicular C cells, and represents 3%-5% of all thyroid cancer cases, occurs
in familial and sporadic forms, and about 13.4% deaths in thyroid cancers was caused by MTC [6]. MTC has diverse features, which can be similar to arbitrary thyroid malignancy and many MTC cases are easily missed or delayed diagnosis due to lacking malignant ultrasonography features [7]. Therefore, to accurately identify patients with MTC is of great significance for the improvement of disease treatments and patients’ prognosis.

Nowadays, regular medical examination in general population are more and more popular in China, and more patients with thyroid nodules were identified through palpation [8]. For newly diagnosed patients, to discriminate benign or malignant nodules was necessary. Ultrasonography is an imaging modality for measuring thyroid nodules and sonographic findings including location, composition, echogenicity, margins, calcifications, shape, vascularity and size are evaluated to stratify malignancy risk based on the Thyroid Imaging Report and Data System (TI-RADS) [9]. TI-RADS helps improve the diagnostic effectiveness of ultrasound and reduce unnecessary preoperative fine-needle aspiration (FNA) biopsies [9]. To date, several classification systems have been proposed to achieve standardized evaluation of clinical ultrasound, including Kwak TI-RADS proposed by Kwak et al. [10], the classification of thyroid diagnosis and treatment guidelines proposed by the American Thyroid Society (ATA) and recently updated American College of Radiology (ACR) TI-RADS [11]. Currently, TI-RADS is mostly applied for distinguishing and diagnosing of benign and malignant thyroid nodules [12]. In a previous study, the diagnostic efficacies of Kwak TI-RADS and ATA guidelines have been compared in the diagnosis of PTC and MTC [13]. ACR TI-RADS has improved the diagnostic performance of ultrasonic prediction of thyroid malignant nodule with high accuracy and high repeatability [14]. Although calcitonin (CT) is the specific serum marker of MTC, it was preoperative performed in patients with suspected nodules (classified as TIRADS 4 or large nodules with a diameter of more than 3 cm). For newly diagnosed patients with thyroid nodules, the diagnostic ability of ACR TI-RADS for MTC still needs investigation.

In this study, the pathologically confirmed benign and malignant thyroid nodules patients were included to compare the ultrasonic characteristics of different types of thyroid nodules, and evaluate the diagnostic value of ACR TI-RADS for MTC and PTC through comparing with Kwak TI-RADS. The findings of our study might provide a reference for the application of ACR TI-RADS in the diagnosis of MTC patients in clinic.

Methods

Study population

In the present study, the clinical data, laboratory inspection data and supersonic inspection data of 565 patients diagnosed with PTC, MTC or benign thyroid nodules were collected in Fujian Provincial Hospital. After excluding patients with a history of other malignancies or receiving adjuvant therapy such as chemotherapy before surgery, 509 patients were finally included. All patients were classified into the benign nodules group (n = 264), the PTC group (n = 189) and the MTC group (n = 56). The study was approved by the Ethics Committee of Fujian Provincial Hospital (K2020-01–027). All methods were performed in accordance with the relevant guidelines and regulations.

Ultrasound and pathological report analysis

High resolution ultrasound examinations of the thyroid were performed by use of a HDI 3000 scanner (Advanced Technology Laboratories, Philips Medical Systems, Bothell, WA) and a HDI 5000 scanner (Philips Medical Systems) with a 5–10 MHz linear array transducer. Radiologists reported the ultrasound records based on the TI-RADS classification [15].

Data collection

The clinical data, laboratory inspection data and supersonic inspection data of 565 patients were collected including age (years), gender, ACR TI-RADS score, ACR TI-RADS classification system (TR1, TR2, TR3, TR4, and TR5), Kwak TI-RADS [type 2, type 3, type 4 (type 4a, type 4b and type 4c), and type 5], carcinoma embryonic antigen (CEA; ng/mL; positive, negative or unknown), calcitonin (CT; pg/mL; positive, negative or unknown), thyroid stimulating hormone (TSH; μU/L; positive, negative or unknown), thyrotropin receptor antibody (TRAb; IU/L; positive, negative or unknown), thyroid peroxidase antibody (TPOAb; IU/mL; positive, negative or unknown), thyroglobulin antibodies (TGAb; IU/mL; positive, negative or unknown), maximum diameter of nodule (cm), composition (cystic, spongy, solid cystic and solid), echogenicity (anechoic, hyperechoic, hypoechoic and markedly hypoechoic), shape (A/T < 1 or A/T ≥ 1), margins (smooth or unclear, irregular or lobulated and extrathyroid extension), calcification (none, coarse calcification, rim calcifications and microcalcifications), and metastatic cervical lymph nodes or not.

Evaluation of the laboratory data

The level of TSH was determined via ultra-sensitive chemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany) (normal ranges 0.27–4.2mIU/L). CT, CEA, TPOAb, TGAb, and TRAb were detected
through immunoassay analysis on a fully automated analyzer Cobas e601 (Roche Diagnostics, Rotkreuz, Switzerland) using electrochemiluminescence (ECL) technology. The Elecsys® Calcitonin assay was standardized against the International Reference Preparation (IRP) World Health Organization 89/620 international standard. The range of CT ≥ 9.52 pg/mL in males or ≥ 6.4 pg/mL in females were considered positive. The range of CEA ≥ 5 ng/mL was regarded as positive. The normal range was considered if TPOAb was 0–34 IU/mL, TRAb was 0–1.75 U/L and TGAb was 0.1–115 IU/mL. All assays were performed in line with the manufacturers’ instructions.

**Definitions of ultrasound characteristics**

The composition, echogenicity, margin and calcification of the nodule were observed from ultrasound thyroid nodule images and evaluated by two physicians with more than 5 years of experience in thyroid ultrasound diagnosis according to ACR TI-RADS and Kwak TI-RADS. In case of disagreements, the physicians reached a consensus through consulting a third person.

**Composition**

Cystic: cystic or almost completely cystic. Spongiform: the presence of very small cysts (50% of the nodule’s volume) that are akin to the fluidfilled spaces in a wet sponge. Solid and cystic: combines 2 features from the lexicon, regardless of the proportion of solid versus cystic components. Solid: solid or almost completely solid [16].

**Echogenicity**

Hypoechoic: hypoechoic relative to thyroid parenchyma (hypoechoic relative to adjacent anterior neck muscle was also involved). Marked hypoechoic: more hypoechoic than strap muscles. Hyperechoic: hyperechoic relative to thyroid parenchyma. Anechoic: absent from the lexicon; applied to cystic or almost completely cystic nodules [17].

**Margin**

Smooth or unclear: obviously discernible smooth edge. Irregular or lobulated: obviously discernible but non-smooth edge showing speculation, microlobulation (the presence of many small lobules on the surface of a nodule), or jagged appearance. Extrathyroidal extension: poorly demarcated margin which cannot be obviously differentiated from adjacent thyroid tissue [17].

**Calcification**

Microcalcification: calcifications that are ≤ 1 mm in diameter, with or without acoustic shadowing, brighter echo than the surrounding thyroid tissue, excluded tiny bright reflectors with a clear-cut comet-tail artifact that was considered colloid, visualized as tiny punctuate hyperechoic foci. Rim calcification: curvilinear hyperechoic structure parallel to the margin of a nodule encompassing > 120 of the circumferences. Coarse calcifications: defined as coarse hyperechoic foci ≥ 1 mm accompanied by acoustic shadowing [17].

**Kwak-TIRADS**

The number of suspicious ultrasound features calculates a score of TIRADS 3, 4A, 4B, 4C, or 5 according to the ultrasound characteristics in Kwak-TIRADS. The risk of malignancy was elevated with the increase of the number of suspicious features (solid or almost solid nodule, hypoechogenicity, irregular margins, presence of microcalcifications, and a taller than wide shape) [14]: TIRADS 3: no suspicious features (risk 1.7%); TIRADS 4A: one suspicious feature (risk 3.3%); TIRADS 4B: two suspicious features (risk 9.2%); TIRADS 4C: three or four suspicious features (risk 44.4–72.4%); TIRADS 5: five suspicious features (risk 87.5%).

**ACR TI-RADS**

ACR TI-RADS includes five ultrasound features (composition, echogenicity, shape, margin, and echogenic foci) and the features are described and weighted by allocating points to get a summed score [18]: TR1: 0 points, benign (aggregate risk level 0.3%); TR2: 2 points, not suspicious (aggregate risk level 1.5%); TR3: 3 points, mildly suspicious (aggregate risk level 4.8%); TR4: 4–6 points, moderately suspicious (aggregate risk level 5.9%-12.8%); TR5: 7 points or more, highly suspicious (aggregate risk level 20.8%-68.4% for 10 points). ACR score was the total score calculated based on the scores of each features in ACR TI-RADS [18]. The detailed scores in each features were displayed as follows: Composition (0 points: Cystic or almost completely cystic; 0 points: Spongiform; 1 point: Mixed cystic and solid; 2 points: Solid or almost completely solid); Echogenicity (0 points: Anechoic; 1 point: Hyperechoic or isoechoic; 2 points: Hypoechoic relative to thyroid parenchyma). Shape (0 points: A/T < 1; 3 points: A/T ≥ 1); Margin (0 points: Smooth or unidentfied; 2 points: Lobulated or irregular;3 points: Extrathyroidal extension); Calcification (0 points: None or or large comet-tail artifacts; 1 point: Macrocacifications; 2 points: Peripheral (rim) calcifications; 3 points: Punctate echogenic foci).

**Statistical analysis**

SAS 9.4 software was used for statistical analysis, and MedCalc software was employed to draw Receiver Operating Characteristic (ROC) curves. All statistical tests were conducted by two-side tests. Shapiro Test was
applied to test the normality of the measurement data. The measurement data with normal distribution were described as Mean ± standard deviation (Mean ± SD), and the non-normal data were displayed as median and quaternary interval [M (Q1, Q3)]. The enumeration data were exhibited as n (%). χ² or Fisher’s exact probability method were employed for comparisons between groups. The area under the curve (AUC) values were analyzed and the ROC curves were drawn to compare the distinguishing efficiency of ACR TI-RADS and KWAK TI-RADS on benign nodules from malignant nodules, MTC from benign nodules, PTC from benign nodules, and MTC from PTC. P < 0.05 was considered to be statistically significant.

Results

The baseline characteristics of all the participants

This study collected the data of 565 pathologically confirmed benign thyroid nodules, PTC and MTC patients. Among them, patients with a history of other malignancies and patients receiving adjuvant therapy such as chemotherapy before surgery were excluded (n = 56), and we finally involved in 509 patients. The screen process was displayed in Fig. 1.

As observed in Table 1, the average age of all participants was 48.22 years old. 264 patients were diagnosed with benign thyroid nodules, accounting for 51.87%, 245 were diagnosed with malignant thyroid nodules, accounting for 48.13%. In patients with malignant thyroid nodules, 189 were PTC patients and 56 were MTC patients. The median score of ACR TI-RADS was 6 points. According to ACR TI-RADS, 54 people belonged to TR1, 30 people belonged to TR2, 66 people belonged to TR3, 116 people belonged to TR4, and 243 people belonged to TR5 class. Based on Kwak TI-RADS, 54 patients belonged to 2 category, 26 patients belonged to 3 category, and 405 patients belonged to 4 category.

Comparisons of baseline data, laboratory inspection data and sonographic features in patients between benign and malignant nodules groups

As exhibited in Table 2, the mean age of patients in the malignant nodules group was lower than the benign nodules group (46.22 years vs 50.08 years). As for the examination of tumor markers, the proportions of people with positive CEA (12.65% vs 2.27%) and CT (12.24% vs 0.76%) were statistically higher in the malignant nodules group than the benign nodules group. As for the thyroid
function examination, the proportions of patients with positive TPOAb (14.69% vs 4.17%), TGAb (11.02% vs 4.17%) and TRAb (84.90% vs 75.38%) was higher in the malignant nodules group than the benign nodules group. The maximum diameter of patients in the malignant nodules was smaller than the benign nodules (0.90 cm vs 3.00 cm). The distributions of patients in different composition, echogenicity, margin, calcification state, and shape in MTC group was statistically different from the benign nodules group (Table 2).

Discrimination values of ACR score, ACR TI-RADS and Kwak TI-RADS for malignant and benign nodules

From the results in Table 4, we identified that the distributions of participants in different malignant suspicious degrees based on ACR TI-RADS or Kwak TI-RADS in the malignant nodules group were different from the benign nodules group. The AUC values of ACR score, ACR TI-RADS and Kwak TI-RADS for distinguishing malignant nodules from benign nodules were 0.914 (95%CI: 0.886–0.937), 0.871 (95%CI: 0.839–0.899) and 0.885 (95%CI: 0.854–0.911), respectively (Fig. 2). The cut-off points were > 5, >TR4 and >4b. The sensitivities of ACR score, ACR TI-RADS and Kwak TI-RADS were 0.935 (95%CI: 0.896–0.962), 0.816 (95%CI: 0.762–0.863) and 0.878 (95%CI: 0.837–0.919), respectively. According to the DeLong test, there was no statistical difference in the efficiency for distinguishing malignant nodules from benign nodules was better than Kwak TI-RADS, but the efficacy of ACR TI-RADS for distinguishing malignant nodules from benign nodules was not better than Kwak TI-RADS (Table 5).

Discrimination values of ACR score, ACR TI-RADS and Kwak TI-RADS for PTC or MTC and patients with benign nodules

The distributions of patients with benign nodules, PTC or MTC based on ACR score, ACR TI-RADS and Kwak TI-RADS were shown in Table 6. In the benign nodules and MTC populations, the AUC values of ACR score, ACR TI-RADS and Kwak TI-RADS for distinguishing MTC from benign nodules were 0.850 (95%CI: 0.811–0.891), 0.820 (95%CI: 0.773–0.860) and 0.832 (95%CI: 0.787–0.872), respectively (Fig. 3). The cut-off points were > 5, >TR4 and >4b. According to the Delong test, there was no statistical difference in the efficiency for distinguishing malignant nodules from benign nodules was better than Kwak TI-RADS (Table 5).

Comparisons of baseline data, laboratory inspection data and sonographic features among MTC, PTC and benign nodules groups

According to the data in Table 3, the mean age of the MTC group was younger than the benign nodules group (48.21 years vs 50.08 years). The proportions of patients with positive CEA (48.21% vs 2.12% vs 2.27%) and CT (51.79% vs 0.53% vs 0.76%) were statistically different in the MTC group, the PTC group and the benign thyroid group. As for the thyroid function examination, the proportions of patients with positive TPOAb (12.50% vs 15.34% vs 4.17%), TGAb (7.14% vs 12.17% vs 4.17%) and TRAb (48.21% vs 95.77% vs 75.38%) were statistically different among the MTC group, the PTC group and benign nodules group. The maximum diameter of patients in the MTC group was smaller than the benign nodules (1.75 cm vs 3.00 cm). The proportions of patients with different composition, echogenicity, margin, calcification state, and shape in MTC group was statistically different from the benign nodules group (Table 2).

| Variables | Total (n = 509) |
|-----------|----------------|
| Age, Mean±SD | 48.22±12.31 |
| Gender, n (%) | |
| Male | 154 (30.26) |
| Female | 355 (69.74) |
| Groups, n (%) | |
| Benign nodules | 264 (51.87) |
| Malignant nodules | 245 (48.13) |
| MTC | 56 (22.86) |
| ACR TI-RADS score, M(Q1,Q3) | 6 (3,9) |
| ACR TI-RADS,n(%) | |
| TR1 | 54 (10.61) |
| TR2 | 30 (5.89) |
| TR3 | 66 (12.97) |
| TR4 | 116 (22.79) |
| TR5 | 243 (47.74) |
| Kwak TI-RADS,n(%) | |
| TIRADS 2 | 54 (10.61) |
| TIRADS 3 | 26 (5.11) |
| TIRADS 4 | 405 (79.57) |
| 4a | 85 (20.99) |
| 4b | 80 (19.75) |
| 4c | 240 (59.26) |
| TIRADS 5 | 24 (4.72) |

ACR American College of Radiology, TI-RADS Thyroid Imaging Report and Data System, MTC Medullary thyroid carcinoma, PTC Papillary thyroid carcinoma
### Table 2: Comparisons of baseline data and laboratory inspection data in patients between benign and malignant nodules groups

| Variable                  | Total (n = 509) | Groups                          | Statistical magnitude | P     |
|---------------------------|-----------------|--------------------------------|-----------------------|-------|
|                           | Benign nodule (n = 264) | Malignant nodule (n = 245)     |                       |       |
| Age, Mean ± SD            | 48.22 ± 12.31    | 50.08 ± 12.32                  | 46.22 ± 12.00         | t = 3.580 < 0.001 |
| Gender, n (%)             |                 |                                |                       | χ² = 2.312 0.128 |
| Male                      | 154 (30.26)      | 72 (27.27)                     | 82 (33.47)            |       |
| Female                    | 355 (69.74)      | 192 (72.73)                    | 163 (66.53)           |       |
| Tumor biomarkers          |                 |                                |                       |       |
| CEA, n (%)                |                 |                                |                       | χ² = 35.577 < .001 |
| Negative                  | 385 (75.64)      | 194 (73.48)                    | 191 (77.96)           |       |
| Positive                  | 37 (7.27)        | 6 (2.27)                       | 31 (12.65)            |       |
| Unknown                   | 87 (17.09)       | 64 (24.24)                     | 23 (9.39)             |       |
| CT, n (%)                 |                 |                                |                       | χ² = 46.369 < .001 |
| Negative                  | 383 (75.25)      | 192 (72.73)                    | 191 (77.96)           |       |
| Positive                  | 32 (6.29)        | 2 (0.76)                       | 30 (12.24)            |       |
| Unknown                   | 94 (18.47)       | 70 (26.52)                     | 24 (9.80)             |       |
| Thyroid function          |                 |                                |                       |       |
| TSH, n(%)                 |                 |                                |                       | χ² = 1.979 0.372 |
| Negative                  | 468 (91.94)      | 247 (93.56)                    | 221 (90.20)           |       |
| Positive                  | 32 (6.29)        | 13 (4.92)                      | 19 (7.76)             |       |
| Unknown                   | 9 (1.77)         | 4 (1.52)                       | 5 (2.04)              |       |
| TPOAb, n(%)               |                 |                                |                       | χ² = 16.880 < .001 |
| Negative                  | 443 (87.03)      | 242 (91.67)                    | 201 (82.04)           |       |
| Positive                  | 47 (9.23)        | 11 (4.17)                      | 36 (14.69)            |       |
| Unknown                   | 19 (3.73)        | 11 (4.17)                      | 8 (3.27)              |       |
| TGAb, n(%)                |                 |                                |                       | χ² = 9.051 0.011 |
| Negative                  | 453 (89.00)      | 242 (91.67)                    | 211 (86.12)           |       |
| Positive                  | 38 (7.47)        | 11 (4.17)                      | 27 (11.02)            |       |
| Unknown                   | 18 (3.54)        | 11 (4.17)                      | 7 (2.86)              |       |
| TRAb, n(%)                |                 |                                |                       | χ² = 7.287 0.026 |
| Negative                  | 3 (0.59)         | 2 (0.76)                       | 1 (0.41)              |       |
| Positive                  | 407 (79.96)      | 199 (75.38)                    | 208 (84.90)           |       |
| Unknown                   | 99 (19.45)       | 63 (23.86)                     | 36 (14.69)            |       |
| Thyroid nodule            |                 |                                |                       |       |
| Maximum diameter of nodule, M (Q1, Q3) | 1.80 (0.80, 3.40) | 3.00 (1.70, 4.00)              | 0.90 (0.60, 1.70)     | Z = -11.205 < 0.001 |
| Composition, n (%)        |                 |                                |                       |       |
| Cystic                    | 54 (10.61)       | 54 (20.45)                     | 0 (0.00)              |       |
| Spongy                    | 4 (0.79)         | 4 (1.52)                       | 0 (0.00)              |       |
| Solid Cystic              | 72 (14.15)       | 60 (22.73)                     | 12 (4.90)             |       |
| Solid                     | 379 (74.46)      | 146 (55.30)                    | 233 (95.10)           |       |
| Echogenicity, n (%)       |                 |                                |                       | χ² = 155.837 < 0.001 |
| Anechoic                  | 55 (10.81)       | 55 (20.83)                     | 0 (0.00)              |       |
| Hyperechoic               | 86 (16.90)       | 80 (30.30)                     | 6 (2.45)              |       |
| Hypoechoic                | 341 (66.99)      | 125 (47.35)                    | 216 (88.16)           |       |
| Markedly Hypoechoic       | 27 (5.30)        | 4 (1.52)                       | 23 (9.39)             |       |
| Shape, n (%)              |                 |                                |                       | χ² = 75.780 < 0.001 |
| A/T < 1                   | 383 (75.25)      | 241 (91.29)                    | 142 (57.96)           |       |
| A/T ≥ 1                   | 126 (24.75)      | 23 (8.71)                      | 103 (42.04)           |       |
| Margin, n(%)              |                 |                                |                       | χ² = 128.221 < 0.001 |
| Smooth or unclear         | 367 (72.10)      | 247 (93.56)                    | 120 (48.98)           |       |
differentiating patients with MTC from patients with benign nodules between ACR TI-RADS and Kwak TI-RADS, while ACR score was better than Kwak TI-RADS in the differentiation of patients with MTC from patients with benign nodules ($Z = 2.404$, $P = 0.016$) (Table 7). In benign nodules and PTC populations, the AUC values of ACR score, ACR TI-RADS and Kwak TI-RADS for differentiating PTC from patients with benign nodules were 0.931 (95%CI: 0.904–0.953), 0.886 (95%CI: 0.853–0.914) and 0.900 (95%CI:0.876–0.925), respectively (Fig. 4), and the cutoff point was > 5, > TR4 and > 4b, respectively. The sensitivities were 0.963 (95%CI: 0.925–0.985), 0.857 (95%CI: 0.799–0.904) and 0.921 (95%CI: 0.882–0.959), respectively. The NPVs were 0.967 (95%CI: 0.942–0.991), 0.891 (95%CI: 0.852–0.930), and 0.935 (95%CI: 0.903–0.967), respectively. The results of Delong Test showed that the discrimination efficiency of ACR score ($Z = 2.869$, $P = 0.004$) and ACR TI-RADS ($Z = 2.235$, $P = 0.025$) for distinguishing PTC was better than for distinguishing MTC from benign nodules (Table 7).

**Discrimination values of ACR score, ACR TI-RADS and Kwak TI-RADS for MTC, PTC or benign nodules**

According to the data in Supplementary Table 1, the AUC values of ACR score, ACR TI-RADS and Kwak TI-RADS for the discrimination of patients with MTC, PTC or benign nodules from patients without MTC, PTC or benign nodules were 0.899 (95%CI: 0.882–0.915), 0.865 (95%CI: 0.846–0.885), and 0.873 (95%CI: 0.854–0.893), respectively (Supplementary Fig. 1). The sensitivities were 0.915 (95%CI: 0.896–0.933), 0.876 (95%CI: 0.856–0.896), and 0.882 (95%CI: 0.862–0.902), respectively. As observed in the results from Delong test, ACR score had better efficiency in discriminating patients with MTC, PTC or benign nodules from patients without MTC, PTC or benign nodules than Kwak TI-RADS ($Z = 1.995$, $P = 0.046$), but ACR TI-RADS showed no significant difference in discriminating patients with MTC, PTC or benign nodules compared with Kwak TI-RADS ($Z = 0.569$, $P = 0.570$).

**Discussion**

We collected the data of 509 patients diagnosed with PTC, MTC or benign thyroid nodules to evaluate the diagnostic performance of ACR score and ACR TI-RADS in different kinds of thyroid nodules especially in MTC. The results delineated that the diagnostic performances of ACR score was better than Kwak TI-RADS in distinguishing malignant nodules from benign nodules. ACR score was better than Kwak TI-RADS in diagnosis of MTC from benign nodules. ACR TI-RADS had similar
| Variable                              | Total (n = 509) | Benign nodule (n = 264) | PTC (n = 189) | MTC (n = 56) | Statistical magnitude | P      |
|--------------------------------------|----------------|------------------------|--------------|--------------|-----------------------|--------|
| **Age, Mean ± SD**                   |                |                        |              |              | F = 7.388             | < .001 |
| **Gender, n (%)**                    |                |                        |              |              | χ² = 4.300            | 0.116  |
| Male                                 | 154 (30.26)    | 72 (27.27)             | 59 (31.22)   | 23 (41.07)   |                       |        |
| Female                               | 355 (69.74)    | 192 (72.73)            | 130 (68.78)  | 33 (58.93)   |                       |        |
| **Tumor biomarkers**                 |                |                        |              |              |                       |        |
| **CEA, n (%)**                       |                |                        |              |              | χ² = 122.338          | < .001 |
| Negative                             | 385 (75.64)    | 194 (73.48)            | 172 (91.01)  | 19 (33.93)   |                       |        |
| Positive                             | 37 (7.27)      | 6 (2.27)               | 4 (2.12)     | 27 (48.21)   |                       |        |
| Unknown                              | 87 (17.09)     | 64 (24.24)             | 13 (6.88)    | 10 (17.86)   |                       |        |
| **CT, n (%)**                        |                |                        |              |              | χ² = 152.534          | < .001 |
| Negative                             | 383 (75.25)    | 192 (72.73)            | 172 (91.01)  | 19 (33.93)   |                       |        |
| Positive                             | 32 (6.29)      | 2 (0.76)               | 1 (0.53)     | 29 (51.79)   |                       |        |
| Unknown                              | 94 (18.47)     | 70 (26.52)             | 16 (8.47)    | 8 (14.29)    |                       |        |
| **Thyroid function**                 |                |                        |              |              | Fisher               | 0.151  |
| **TSH, n (%)**                       |                |                        |              |              |                       |        |
| Negative                             | 468 (91.94)    | 247 (93.56)            | 171 (90.48)  | 50 (89.29)   |                       |        |
| Positive                             | 32 (6.29)      | 13 (4.92)              | 16 (8.47)    | 3 (5.36)     |                       |        |
| Unknown                              | 9 (1.77)       | 4 (1.52)               | 2 (1.06)     | 3 (5.36)     |                       |        |
| **TPOAb, n (%)**                     |                |                        |              |              | χ² = 27.822          | < .001 |
| Negative                             | 443 (87.03)    | 242 (91.67)            | 158 (83.60)  | 43 (76.79)   |                       |        |
| Positive                             | 47 (9.23)      | 11 (4.17)              | 29 (15.34)   | 7 (12.50)    |                       |        |
| Unknown                              | 19 (3.73)      | 11 (4.17)              | 2 (1.06)     | 6 (10.71)    |                       |        |
| **TGAb, n (%)**                      |                |                        |              |              | χ² = 22.977          | < .001 |
| Negative                             | 453 (89.00)    | 242 (91.67)            | 165 (87.30)  | 46 (82.14)   |                       |        |
| Positive                             | 38 (7.47)      | 11 (4.17)              | 23 (12.17)   | 4 (7.14)     |                       |        |
| Unknown                              | 18 (3.54)      | 11 (4.17)              | 2 (1.06)     | 6 (10.71)    |                       |        |
| **TRAb, n (%)**                      |                |                        |              |              | χ² = 74.632          | < .001 |
| Negative                             | 3 (0.59)       | 2 (0.76)               | 1 (0.53)     | 0 (0.00)     |                       |        |
| Positive                             | 407 (79.96)    | 199 (75.38)            | 181 (95.77)  | 27 (48.21)   |                       |        |
| Unknown                              | 99 (19.45)     | 63 (23.86)             | 7 (3.70)     | 29 (51.79)   |                       |        |
| **Thyroid nodule**                   |                |                        |              |              |                       |        |
| Maximum diameter of nodule, M (Q1, Q3) | 1.80 (0.80, 3.40) | 3.00 (1.70, 4.00)    | 0.80 (0.60, 1.40) | 1.75 (0.90, 3.15) | Z = 5.137             | < .001 |
| Composition, n (%)                   |                |                        |              |              |                       |        |
| Cystic                               | 54 (10.61)     | 54 (20.45)             | 0 (0.00)     | 0 (0.00)     |                       |        |
| Spongy                               | 4 (0.79)       | 4 (1.52)               | 0 (0.00)     | 0 (0.00)     |                       |        |
| Solid Cystic                         | 72 (14.15)     | 60 (22.73)             | 3 (1.59)     | 9 (16.07)    |                       |        |
| Solid                                | 379 (74.46)    | 146 (55.30)            | 186 (98.41)  | 47 (83.93)   |                       |        |
| Echogenicity, n (%)                  |                |                        |              |              |                       | < .001 |
| Anechoic                             | 55 (10.81)     | 55 (20.83)             | 0 (0.00)     | 0 (0.00)     |                       |        |
| Hyperechoic                          | 86 (16.90)     | 80 (30.30)             | 4 (2.12)     | 2 (3.57)     |                       |        |
| Hypoechoic                           | 341 (66.99)    | 125 (47.35)            | 172 (91.01)  | 44 (78.57)   |                       |        |
| Markedly Hypoechoic                  | 27 (5.30)      | 4 (1.52)               | 13 (6.88)    | 10 (17.86)   |                       |        |
| Shape, n (%)                         |                |                        |              |              | χ² = 22.950          | < .001 |
| A/T < 1                              | 383 (75.25)    | 241 (91.29)            | 94 (49.74)   | 48 (85.71)   |                       |        |
| A/T ≥ 1                              | 126 (24.75)    | 23 (8.71)              | 95 (50.26)   | 8 (14.29)    |                       |        |
| Margin, n (%)                        |                |                        |              |              | χ² = 7.555           | < .001 |
| Smooth or unclear                    | 367 (72.10)    | 247 (93.56)            | 87 (46.03)   | 33 (58.93)   |                       |        |
| Irregular or lobulated               | 107 (21.02)    | 17 (6.44)              | 78 (41.27)   | 12 (21.43)   |                       |        |
| Extra thyroid extension              | 35 (6.88)      | 0 (0.00)               | 24 (12.70)   | 11 (19.64)   |                       |        |
diagnostic efficacy with Kwak TI-RADS in discriminating MTC or PTC from benign nodules.

Currently, the diagnosis of benign or malignant thyroid nodules in patients remains to be a challenge [19]. The TI-RADS for risk stratification is widely used for evaluating the suspicious degrees of malignant thyroid nodules through scoring the number or the combination of a variety of suspicious ultrasound criteria with high accuracy and repeatability [15, 18, 20, 21]. Globally, several standardized reporting systems have been proposed including 2015 ATA guideline, Korean Thyroid Association/Korean Society of Thyroid Radiology (KTA/KSThr) guideline, Kwak TI-RADS and ACR TI-RADS [18, 22, 23]. A previous study was conducted to compare the diagnostic ability of the KSThr guideline, European Thyroid Society (ETA) and ACR TI-RADS in distinguishing benign from malignant thyroid lesions, which revealed that KSTHR TI-RADS had the best diagnostic specificity, while ACR TI-RADS had the best sensitivity [24]. As shown in the study of Zhang et al., the AUC value of the diagnostic performance of ACR TI-RADS in thyroid nodules was 0.907, which was higher than Kwak TI-RADS (0.904), ATA guidelines (0.894) and KTA/KSThr guidelines (0.888) [25]. The sensitivity (85.7%) and NPV (98.3%) of ACR TI-RADS were both higher than EU TI-RADS and the specificity of ACR TI-RADS (51.1%) was higher than Kwak TI-RADS [26]. In this study, we found that compared with Kwak TI-RADS, ACR TI-RADS had better specificity and PPV in differentiating the benign and malignant thyroid nodules.

A recent study delineated that Kwak TI-RADS and ATA TI-RADS had similar performance in the diagnosis of MTC, but the performance was worse than in the diagnosis of PTC [13]. In the current study, the diagnosis performance of ACR TI-RADS in distinguishing

| Variable                          | Total (n = 509) | Benign nodule (n = 264) | PTC (n = 189) | MTC (n = 56) | Statistical magnitude | P   |
|-----------------------------------|----------------|-------------------------|---------------|-------------|----------------------|-----|
| Calcification, n (%)              | < 0.001        |                         |               |             |                      |     |
| None                              | 270 (53.05)    | 193 (73.11)             | 59 (31.22)    | 18 (32.14)  |                      |     |
| Coarse calcifications             | 47 (9.23)      | 34 (12.88)              | 11 (5.82)     | 2 (3.57)    |                      |     |
| Rim calcifications                | 12 (2.36)      | 4 (1.52)                | 7 (3.70)      | 1 (1.79)    |                      |     |
| Micro calcifications              | 180 (35.36)    | 33 (12.50)              | 59 (31.22)    | 18 (32.14)  |                      |     |
| Metastatic lymph nodes, n (%)     | $\chi^2 = 5.825$ |                         |               |             |                      | < 0.001 |
| No                                | 451 (88.61)    | 264 (100.00)            | 151 (79.89)   | 36 (64.29)  |                      |     |
| Yes                               | 58 (11.39)     | 0 (0.00)                | 38 (20.11)    | 20 (35.71)  |                      |     |

Table 3 (continued)

Table 4 Comparison of pathological data of ACR, ACR TI-RADS and Kwak TI-RADS on benign nodules and malignant nodules

| Variable        | Total (n = 509) | Benign nodule (n = 264) | Malignant nodule (n = 245) | Statistical magnitude | P   |
|-----------------|----------------|-------------------------|----------------------------|----------------------|-----|
| ACR score, M (Q1, Q3) | 6 (3, 9)       | 3 (2, 5)                 | 9 (7, 10)                 | Z = -16.248          | < 0.001 |
| ACR-TI-RADS, n (%)  |                |                         |                            | Z = -15.471          | < 0.001 |
| TR1              | 54 (10.61)     | 54 (20.45)               | 0 (0.00)                  |                      |     |
| TR2              | 30 (5.89)      | 29 (10.98)               | 1 (0.41)                  |                      |     |
| TR3              | 66 (12.97)     | 62 (23.48)               | 4 (1.63)                  |                      |     |
| TR4              | 116 (22.79)    | 76 (28.79)               | 40 (16.33)                |                      |     |
| TR5              | 243 (47.74)    | 43 (16.29)               | 200 (81.63)               |                      |     |
| Kwak TI-RADS, n (%) |                |                         |                            | Z = -15.956          | < 0.001 |
| TIRADS 2         | 54 (10.61)     | 54 (20.45)               | 0 (0.00)                  |                      |     |
| TIRADS 3         | 26 (5.11)      | 25 (9.47)                | 1 (0.41)                  |                      |     |
| TIRADS 4a        | 85 (16.70)     | 80 (30.30)               | 5 (2.04)                  |                      |     |
| TIRADS 4b        | 80 (15.72)     | 56 (21.21)               | 24 (9.80)                 |                      |     |
| TIRADS 4c        | 240 (47.15)    | 49 (18.56)               | 191 (77.96)               |                      |     |
| TIRADS 5         | 24 (4.72)      | 0 (0.00)                 | 24 (9.80)                 |                      |     |

Carcinoma embryonic antigen, CT Calcitonin, TSH Thyroid stimulating hormone, TRAb Thyrotrpin receptor antibody, TPOAb Thyroid peroxidase antibody, TGAb Thyroglobulin antibodies
MTC and PTC from benign nodules was compared with Kwak TI-RADS, which showed that the diagnosis value of ACR TI-RADS on MTC or PTC was comparable with Kwak TI-RADS, and ACR TI-RADS had better diagnosis efficiency on PTC than MTC. MTC and PTC may have some overlapping sonographic features of malignancy which may result in the misdiagnosis of MTC [27]. Here in our study, both ACR TI-RADS and Kwak TI-RADS had average diagnostic abilities in differentiating MTC from PTC. This maybe because due to the high prevalence of PTC, most of the present classification systems mainly focus on differentiating PTC [28]. In the present study, the ACR score showed better diagnostic abilities on distinguishing malignant nodules from benign nodules, MTC from benign nodules, and MTC from PTC. Kwak TI-RADS diagnosed the malignancy via calculating the malignant features, which has high sensitivity and it is simple and easy to conduct. But the malignant degree of the sonographic features is not shown, so it was more applied for screening different kinds of thyroid nodules [29]. ACR TI-RADS was calculated via cumulative scores of different sonographic features, different features were scored differently, reflecting the malignant risk degrees of different sonographic features, which is more complicated and had higher specificity, it is more commonly used for the diagnosis of different kinds of thyroid nodules [29].
The present study assessed the discriminative efficacies of ACR score and ACR TI-RADS on malignant nodules from benign nodules, MTC from PTC or benign nodules, as well as PTC from benign nodules compared with Kwak TI-RADS. ACR score used single score to diagnose malignant nodules from benign nodules, and MTC from benign nodules with AUC values of 0.914 and 0.850, respectively, which was better than ACR TI-RADS and Kwak TI-RADS. The AUC value of ACR score were 0.650 in differentiating MTC from PTC, and in the future, the

| Variables | Total (n = 509) | Groups | Benign nodule (n = 264) | PTC (n = 189) | MTC (n = 56) |
|-----------|----------------|--------|------------------------|---------------|--------------|
| ACR score, M(Q1,Q3) | 6 (3,9) | 3 (2,5) | 9 (7,10) | 7 (6,9) |
| ACR TI-RADS, n (%) | | | | | |
| TR1 | 54 (10.61) | 54 (20.45) | 0 (0.00) | 0 (0.00) |
| TR2 | 30 (5.89) | 29 (10.98) | 0 (0.00) | 1 (1.79) |
| TR3 | 66 (12.97) | 62 (23.48) | 0 (0.00) | 4 (7.14) |
| TR4 | 116 (22.79) | 76 (28.79) | 27 (14.29) | 13 (23.21) |
| TR5 | 243 (47.74) | 43 (16.29) | 162 (85.71) | 38 (67.86) |
| Kwak TI-RADS, n(%) | | | | | |
| TI-RADS 2 | 54 (10.61) | 54 (20.45) | 0 (0.00) | 0 (0.00) |
| TI-RADS 3 | 26 (5.11) | 25 (9.47) | 0 (0.00) | 1 (1.79) |
| TI-RADS 4a | 85 (16.70) | 80 (30.30) | 1 (0.53) | 4 (7.14) |
| TI-RADS 4b | 80 (15.72) | 56 (21.21) | 14 (7.41) | 10 (17.86) |
| TI-RADS 4c | 240 (47.15) | 49 (18.56) | 153 (80.95) | 38 (67.86) |
| TI-RADS 5 | 24 (4.72) | 0 (0.00) | 21 (11.11) | 3 (5.36) |

ACR American College of Radiology, TI-RADS Thyroid Imaging Report and Data System, MTC Medullary thyroid carcinoma, PTC Papillary thyroid carcinoma

Fig. 3 The ROC curve of the efficiencies of ACR score, ACR TI-RADS and Kwak TI-RADS in distinguishing MTC from benign nodules
Table 7 Diagnostic performances of ACR score, ACR TI-RADS and Kwak TI-RADS in the diagnosis of MTC or PTC

| Variables                  | AUC (95%CI)   | Cutoff | Sensitivity (95%CI) | Specificity (95%CI) | PPV (95%CI)  | NPV (95%CI)  | Z      | P     | Z*     | P*   |
|----------------------------|---------------|--------|---------------------|---------------------|--------------|--------------|--------|-------|--------|------|
| ACR score                  | 0.850 (0.811–0.891) | > 5    | 0.839 (0.717–0.924) | 0.765 (0.709–0.815) | 0.431 (0.709–0.815) | 0.957 (0.709–0.815) | 2.404  | 0.016 |
| ACR TI-RADS                | 0.820 (0.773–0.860) | > TR4  | 0.679 (0.540–0.797) | 0.837 (0.787–0.880) | 0.469 (0.360–0.578) | 0.925 (0.891–0.958) | 1.497  | 0.134 |
| Kwak TI-RADS               | 0.832 (0.787–0.872) | > 4b   | 0.732 (0.597–0.842) | 0.814 (0.762–0.859) | 0.456 (0.353–0.558) | 0.935 (0.903–0.967) | -      | -     |
| ACR score                  | 0.931 (0.904–0.953) | > 5    | 0.963 (0.925–0.985) | 0.765 (0.709–0.815) | 0.746 (0.691–0.801) | 0.967 (0.942–0.991) | 1.754  | 0.079 |
| ACR TI-RADS                | 0.886 (0.853–0.914) | > TR4  | 0.857 (0.799–0.904) | 0.837 (0.787–0.880) | 0.790 (0.735–0.846) | 0.891 (0.852–0.930) | 0.701  | 0.483 |
| Kwak TI-RADS               | 0.900 (0.876–0.925) | > 4b   | 0.921 (0.882–0.959) | 0.814 (0.767–0.861) | 0.780 (0.726–0.835) | 0.935 (0.903–0.967) | -      | -     |

Z and P depicted the results compared with Kwak TI-RADS
Z* and P* revealed the results of ACR score a and ACR TI-RADS a compared with ACR score b and ACR TI-RADS b

ACR American College of Radiology, TI-RADS Thyroid Imaging Report and Data System, PPV Positive predictive value, NPV Negative predictive value, MTC Medullary thyroid carcinoma, PTC Papillary thyroid carcinoma

a Diagnostic performance of ACR score, ACR TI-RADS and Kwak TI-RADS for MTC compared with benign nodules
b Diagnostic performance of ACR score, ACR TI-RADS and Kwak TI-RADS for PTC compared with benign nodules
Fig. 4 The ROC curve of the efficiencies of ACR score, ACR TI-RADS and Kwak TI-RADS in distinguishing PTC from benign nodules.

Fig. 5 The ROC curve of the diagnostic efficiencies of ACR score, ACR TI-RADS and Kwak TI-RADS for MTC patients with MTC or PTC.
application of ACR score combined with other diagnostic methods might improve the diagnostic performance. ACR TI-RADS had a higher diagnostic value for benign nodules and malignant nodules than Kwak TI-RADS. MTC is a highly malignant, and patients underwent surgery can be cured except the advanced MTC, so early diagnosis is important for improving the prognosis [30]. The findings of this study might provide a reference for using ACR TI-RADS for newly diagnosed thyroid nodule patients to distinguish malignant nodules, benign nodules, PTC and MTC based on ultrasound data. For patients with highly-suspected MTC based on the results from ACR TI-RADS, CT assay was recommended as it is considered to be a sensitive and specific marker for the diagnosis of MTC [31]. Using of ACR TI-RADS might also help reduce the unnecessary biopsies in FNA, and decrease the waste of medical resources and the psychological burden to patients.

Several limitations existed in this study. Firstly, the sample size was small, which might decrease the statistical power of our results. Secondly, ACR score was derived from ACR TI-RADS, the efficacy of it should be verified. Studies with large scale of sample size were required to validate the results of our study.

Conclusions

Our study collected the data of 509 patients diagnosed with PTC, MTC or benign thyroid nodules and assessed the diagnostic performances of ACR score and ACR TI-RADS. The data depicts that the ACR score performed the best, followed ex aequo by the ACR and Kwak TI-RADS in discriminating patients with malignant nodules from benign nodules and patients with MTC from PTC. The findings of this study might provide a reference for the application of ACR score and ACR TI-RADS in the diagnosis of MTC, PTC and benign nodules.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12902-022-01053-z.

Table 8 Diagnostic performances of ACR score, ACR TI-RADS and Kwak TI-RADS in the diagnosis of PTC from MTC

| Variables        | AUC area (95%CI) | Cutoff | Sensitivity (95%CI) | Specificity (95%CI) | PPV (95%CI) | NPV (95%CI) | Z    | P     |
|------------------|-----------------|--------|---------------------|---------------------|-------------|-------------|------|-------|
| ACR score        | 0.650 (0.565–0.734) | ≤ 8    | 0.696 (0.576–0.817) | 0.577 (0.506–0.647) | 0.328 (0.243–0.412) | 0.865 (0.805–0.925) | 0.669 | 0.504 |
| ACR TI-RADS      | 0.596 (0.527–0.664) | ≤ TR4  | 0.321 (0.199–0.444) | 0.857 (0.807–0.907) | 0.400 (0.257–0.543) | 0.810 (0.756–0.864) | 0.345 | 0.730 |
| Kwak TI-RADS     | 0.613 (0.545–0.681) | ≤ 4b   | 0.268 (0.152–0.384) | 0.921 (0.882–0.959) | 0.500 (0.321–0.679) | 0.809 (0.757–0.862) |      |       |

ACR American College of Radiology, TI-RADS Thyroid Imaging Report and Data System, PPV Positive predictive value, NPV Negative predictive value, MTC Medullary thyroid carcinoma, PTC Papillary thyroid carcinoma

Acknowledgements

Not applicable.

Authors’ contributions

Ziwei Zhang and Ning Lin designed the study. Ziwei Zhang and Ning Lin collected, analyzed and interpreted the data. Ning Lin critically reviewed, edited and approved the manuscript. Both authors read and approved the final manuscript.

Funding

This study was supported by Fujian Provincial Department of Finance (K2020-01-027). Written informed consent has been obtained from all participants. All methods were performed in accordance with the relevant guidelines and regulations.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to limitations of ethical approval involving the patient data and anonymity but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Fujian Provincial Hospital (K2020-01-027). Written informed consent has been obtained from all participants. All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Informed consent for publication was obtained from all participants.

Competing interests

The authors declare that they have no competing interests.

Received: 12 July 2021 Accepted: 18 May 2022

Published online: 31 May 2022

References

1. Grani G, Sponziello M, Peccce V, Ramundo V, Durante C. Contemporary thyroid nodule evaluation and management. J Clin Endocrinol Metab. 2020;105(9):2869–83.
2. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. J Endocrinol Invest. 2010;33(5 Suppl):1–50.
3. Smith-Bindman R, Lebda P, Feldstein VA, Sellami D, Goldstein RB, Brasic N, et al. Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study. JAMA Intern Med. 2013;173(19):1788–96.
4. Fisher SB, Perrier ND. The incidental thyroid nodule. CA Cancer J Clin. 2018;68(2):97–105.
5. Yu J, Deng Y, Liu T, Zhou J, Jia X, Xiao T, et al. Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics. Nat Commun. 2020;11(1):4807.
6. Valderrabano P, Klippenstein DL, Toutrelot JB, Ma Z, Thompson ZJ, Lilienfeld HS, et al. New American Thyroid Association Sonographic patterns

Additional file 1.

Additional file 2.
for thyroid nodules perform well in medullary thyroid carcinoma: institutional experience, systematic review, and meta-analysis. Thyroid. 2016;26(8):1095–100.
7. Appetecchia M, Lauretta R, Barnabei A, Pieruzzi L, Terrenato I, Cavedon E, et al. Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (IMTC/PTC): An Italian Multicenter Study. Cancers (Basel). 2019;11(10):1516.
8. Liu C, Chen S, Yang Y, Shao D, Peng W, Wang Y, Chen Y, Wang Y. The value of the computer-aided diagnosis system for thyroid lesions based on computed tomography images. Quant Imaging Med Surg. 2019;9(4):642–53.
9. Zhang Y, Zhou P, Tian SM, Zhao YF, Li JL, Li L. Usefulness of combined use of contrast-enhanced ultrasound and TI-RADS classification for the differentiation of benign from malignant lesions of thyroid nodules. Eur Radiol. 2017;27(4):1527–36.
10. Huang S, Meng N, Pan M, Yu B, Liu J, Deng K, Hu M, Zhou H, Qin C. Diagnostic performances of the KWA/TIRADS classification, elasticity score, and Bethesda System for Reporting Thyroid Cytopathology of TI-RADS category 4 thyroid nodules. Int J Clin Exp Pathol. 2020;13(5):1159–68.
11. Zhang WB, Xu HX, Zhang YF, Guo LH, Xu SH, Zhao CK, et al. Comparisons of ACR TI-RADS, ATA guidelines, Kwak TI-RADS, and KTA/KSHTI guidelines in malignancy risk stratification of thyroid nodules. Clin Hemorheol Microcirc. 2020;75(2):219–32.
12. Jin Z, Zhu Y, Zhang S, Xie F, Zhang M, Zhang Y, et al. Ultrasound Computer-Aided Diagnosis (CAD) Based on the Thyroid Imaging Reporting and Data System (TI-RADS) to distinguish benign from malignant thyroid nodules and the diagnostic performance of radiologists with different diagnostic experience. Med Sci Monit. 2020;26:e918452.
13. Li J, Li H, Yang Y, Zhang X, Qian L. The KWA/TI-RADS and 2015 ATA guidelines for medullary thyroid carcinoma: combined with cell block-assisted ultrasound-guided thyroid fine-needle aspiration. Clin Endocrinol (Oxf). 2020;92(5):450–60.
14. Basha MAA, Alnaggar AA, Refaat R, El-Maghraby AM, Abd Elhamed ME, et al. The validity and reproducibility of the thyroid imaging reporting and data system (TI-RADS) in categorization of thyroid nodules: multicentre prospective study. Eur J Radiol. 2019;117:184–92.
15. Kwak JY, Han KH, Yoon JH, Moon HI, Son EJ, Park SH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology. 2011;260(3):892–9.
16. Middleton WD, Teeffy SA, Reading CC, Langer JE, Beland MD, Szabunio MM, Dessser TS. Comparison of Performance Characteristics of American College of Radiology TI-RADS, Korean Society of Thyroid Radiology TI-RADS, and American Thyroid Association Guidelines. AJR Am J Roentgen. 2018;210(5):1148–54.
17. Xiao J, Xiao Q, Cong W, Li T, Ding S, Shao C, Zhang Y, Liu J, Wu M, Jia H. Discriminating malignancy in thyroid nodules: the nomogram versus the Kwak and ACR TI-RADS. Otolaryngol Head Neck Surg. 2020;163(6):1156–65.
18. Tessier FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teeffy SA, et al ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS committee. J Am Coll Radiol. 2017;14(5):587–95.
19. Canforotta M, Moote D, Finck C, Riba-Wolman R, Thaker S, Lerro TJ, et al. McGill Thyroid Nodule Score in differentiating benign and malignant pediatric thyroid nodules: a pilot study. Otolaryngol Head Neck Surg. 2017;157(4):589–95.
20. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):11–133.
21. Russ G, Roeyn B, Bigorgne C, Rouxel A, Bienvenu-Perrard M, Lennhardt L. Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol. 2013;168(5):649–55.
22. Haugen BR. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017;123(3):372–81.
23. Shin, JH, Baek, JH, Chung, J, Ha, EJ, Kim, JH, Lee, YH, et al. Ultrasoundography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol. 2016;17(3):370–95.
24. Xu T, Wu Y, Wu RX, Zhang YZ, Gu JY, Ye XH, et al. Validation and comparison of three newly-released Thyroid Imaging Reporting and Data Systems for cancer risk determination. Endocrine. 2019;64(4):299–307.
25. Zhang WB, Xu W, Fu WJ, He BL, Liu H, Deng WF. Comparison of ACR TI-RADS, Kwak TI-RADS, ATA guidelines and KTA/KSHTI guidelines in combination with SWE in the diagnosis of thyroid nodules. Clin Hemorheol Microcirc. 2021;78(2):163–74.
26. Tan L, Tan YS, Tan S. Diagnostic accuracy and ability to reduce unnecessary FNAC: a comparison between four Thyroid Imaging Reporting Data System (TI-RADS) versions. Clin Imaging. 2020;65:133–7.
27. Trimbo P, Treglia G, Guidobaldi L, Romenalli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol. 2015;82(2):280–5.
28. Trimbo P, Giovanella L, Crescenzii A, Romenalli F, Valabrega S, Spriano G, et al. Medullary thyroid cancer diagnosis: an appraisal. Head Neck. 2014;36(8):1216–23.
29. Yang R, Zou X, Zeng H, Zhao Y, Ma X. Comparison of diagnostic performance of five different ultrasound TI-RADS classification guidelines for thyroid nodules. Front Oncol. 2020;10:598225.
30. Wang X, Li C, Huang L, Shui CY, Liu W, Cai YC, et al. Progression of diagnosis and treatment of medullary thyroid carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019;54(4):306–10.
31. Giovanella L, Fontana M, Keller F, Verbarg FA, Ceriani L. Clinical performance of calcitonin and procalcitonin Elecsys(®) immunosassays in patients with medullary thyroid carcinoma. Clin Chem Lab Med. 2021;59(4):743–7.